Frontiers of Medicine
doi:10.1007/s11684-023-1016-8
Abstract:
Here, we reposition decitabine for triple-negative breast cancer (TNBC), a subtype with frequent p53In a prospective DEciTabinE and Carboplatin in TNBC (DETECT) trial (NCT03295552), decitabine with carboplatinIn the DETECT trial, decitabine induced strong immune responses featuring the striking upregulation ofOur integrative studies reveal the potential of repurposing decitabine for the treatment of p53-mutatedTNBC and suggest IRF7 as a potential biomarker for decitabine-based treatments.